We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Product News

Critical Outcome Technologies Inc. Announces Definitive Proof of COTI-2’s Target and Single

COTI-2 is the first drug developed using the Company’s proprietary artificial intelligence system, CHEMSAS®.
Product News

SwissTrace Launches Twilite, an Innovative Product to Help in the Diagnosis Of Diseases, In Drug Development and Basic Research

A new and highly sensitive nuclear medicine blood sampler measures the time-course of radioactivity in whole blood.
Product News

PRECOS Partners with Reliable Cancer Therapies to Provide Rigorous Scientific Evidence for Complementary Cancer Medicines

PRECOS provide drug efficacy work to support RCT's research on complementary medicines.
Product News

Radient Pharmaceuticals' Onko-Sure® Cancer Test Available Through NeoloMed BioSciences

Increased availability of Onko-Sure® in Northeast US.
Product News

Endomagnetics Secures Funding for Expansion and Product Launch

Technology will extend the availability of best practice in cancer staging globally.
Product News

Sigma® Life Science Launches Genetically Modified Human Cell Lines for Breast Cancer Research

CompoZr® ZFN-modified breast cancer cell lines will accelerate drug discovery and enhance basic research.
Product News

Final Winners of BMG LABTECH's SPECTROstar Nano Competition

Dr. Michael Campa has proposed to use a new microplate reader from BMG LABTECH to investigate one such mechanism.
Product News

FDA Approves Immunovaccine's Application for a Phase I/II Clinical Trial for an Ovarian Cancer Vaccine

DPX-Survivac will be tested in patients with ovarian cancer.
Product News

First Patients are Vaccinated in IMPRINT, immatics’ Pivotal Phase III Trial with IMA901 in Patients with RCC

The trial is designed to demonstrate the overall survival benefit of IMA901 in combination with standard first-line therapy in RCC patients.
Product News

Adaptimmune Announces Opening of Phase I/II Clinical Trial for Metastatic Melanoma at Washington University, St. Louis

Trial could generate future alternative treatment for metastatic melanoma.
Advertisement